Modulation of Acid Sphingomyelinase in Melanoma Reprogrammes the Tumour Immune Microenvironment

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Assi, Emma ^a,b   Cervia, Davide ^c,d   Bizzozero, Laura ^a,e   Capobianco, Annalisa ^b   Pambianco, Sarah ^c   Morisi, Federica ^c   De Palma, Clara ^c   Moscheni, Claudia ^c   Pellegrino, Paolo ^c   Clementi, Emilio ^a,c   Perrotta, Cristiana ^c  

^a SCIENTIFIC INSTITUTE   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF TUSCIA   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GLYCOPROTEIN P 15095; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERMES ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; SPHINGOMYELIN PHOSPHODIESTERASE; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DOWN REGULATION; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; IMMUNOMODULATION; IN VIVO STUDY; LYMPHOCYTE HOMING; LYMPHOCYTIC INFILTRATION; MELANOMA; MELANOMA CELL; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; EXPERIMENTAL MELANOMA; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; NUCLEAR REPROGRAMMING; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLULAR REPROGRAMMING; FEMALE; IMMUNE TOLERANCE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; SPHINGOMYELIN PHOSPHODIESTERASE; TUMOR MICROENVIRONMENT;

EID: 84935830836     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/370482     Document Type: Article

References (61)

1. D. Grossman and D. C. Altieri, "Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets, " Cancer and Metastasis Reviews, vol. 20, no. 1-2, pp. 3-11, 2001.
2. A. H. Enk, J. C. Becker, and G. Schuler, "Immunotherapy of malignant melanoma-basic principles and novel therapeutic approaches, " Journal der Deutschen Dermatologischen Gesellschaft, vol. 4, no. 8, pp. 635-645, 2006.
3. R. Wu, M.-A. Forget, J. Chacon, et al., "Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook, " The Cancer Journal, vol. 18, no. 2, pp. 160-175, 2012.
4. V. Umansky, A. Sevko, C. Gebhardt, and J. Utikal, "Myeloidderived suppressor cells in malignant melanoma, " Journal der Deutschen Dermatologischen Gesellschaft, vol. 12, no. 11, pp. 1021-1027, 2014.
5. C. Meyera, A. Sevko, M. Ramacher, et al., "Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model, " Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 41, pp. 17111-17116, 2011.
6. S. I. Grivennikov, F. R. Greten, and M. Karin, "Immunity, inflammation, and cancer, " Cell, vol. 140, no. 6, pp. 883-899, 2010.
7. A. A. Navarini-Meury and C. Conrad, "Melanoma and innate immunity-active inflammation or just erroneous attraction?: melanoma as the source of leukocyte-attracting chemokines, " Seminars in Cancer Biology, vol. 19, no. 2, pp. 84-91, 2009.
8. K. N. Kodumudi, A. Weber, A. A. Sarnaik, and S. Pilon-Thomas, "Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model ofmelanoma, " Journal of Immunology, vol. 189, no. 11, pp. 5147-5154, 2012.
9. R. Wesolowski, J. Markowitz, and W. E. Carson III, "Myeloid derived suppressor cells-a new therapeutic target in the treatment of cancer, " Journal for ImmunoTherapy of Cancer, vol. 1, article 10, 2013.
10. B. Ogretmen and Y. A. Hannun, "Biologically active sphingolipids in cancer pathogenesis and treatment, " Nature Reviews Cancer, vol. 4, no. 8, pp. 604-616, 2004.
11. C. De Palma and C. Perrotta, "Ceramide as a target of chemotherapy: its role in apoptosis and autophagy, " Clinical Lipidology, vol. 7, no. 1, pp. 111-119, 2012.
12. L. Riboni, R. Campanella, R. Bassi, et al., "Ceramide levels are inversely associated with malignant progression of human glial tumors, " Glia, vol. 39, no. 2, pp. 105-113, 2002.
13. A. Prinetti, D. Millimaggi, S. DAscenzo, et al., "Lack of ceramide generation and altered sphingolipid composition are associated with drug resistance in human ovarian carcinoma cells, " Biochemical Journal, vol. 395, no. 2, pp. 311-318, 2006.
14. E. L. Smith and E. H. Schuchman, "The unexpected role of acid sphingomyelinase in cell death and the pathophysiology of common diseases, " The FASEB Journal, vol. 22, no. 10, pp. 3419-3431, 2008.
15. A. E. M. Mahdy, J. C. Cheng, J. Li, et al., "Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer, " Molecular Therapy, vol. 17, no. 3, pp. 430-438, 2009.
16. V. Edmond, F. Dufour, G. Poiroux, et al., "Downregulation of ceramide synthase-6 during epithelial-to-mesenchymal transition reduces plasmamembrane fluidity and cancer cellmotility, " Oncogene, vol. 34, no. 19, pp. 996-1005, 2014.
17. N. H. T. Petersen, O. D. Olsen, L. Groth-Pedersen, et al., "Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase, " Cancer Cell, vol. 24, no. 3, pp. 379-393, 2013.
18. L. Bizzozero, D. Cazzato, D. Cervia, et al., "Acid sphingomyelinase determines melanoma progression and metastatic behaviour via the microphtalmia-associated transcription factor signalling pathway, " Cell Death and Differentiation, vol. 21, no. 4, pp. 507-520, 2013.
19. C. Perrotta, L. Bizzozero, S. Falcone, et al., "Nitric oxide boosts chemoimmunotherapy via inhibition of acid sphingomyelinase in a mouse model of melanoma, " Cancer Research, vol. 67, no. 16, pp. 7559-7564, 2007.
20. C. Perrotta, M. Buldorini, E. Assi, et al., "The thyroid hormone triiodothyronine controls macrophage maturation and functions: protective role during inflammation, " The American Journal of Pathology, vol. 184, no. 1, pp. 230-247, 2014.
21. C. de Palma, F. Morisi, S. Pambianco, et al., "Deficient nitric oxide signalling impairs skeletal muscle growth and performance: involvement of mitochondrial dysregulation, " Skeletal Muscle, vol. 4, article 22, 2014.
22. D. Cazzato, E. Assi, C. Moscheni, et al., "Nitric oxide drives embryonic myogenesis in chicken through the upregulation of myogenic differentiation factors, " Experimental Cell Research, vol. 320, no. 2, pp. 269-280, 2014.
23. C. Sciorati, T. Touvier, R. Buono, et al., "Necdin is expressed in cachectic skeletal muscle to protect fibers from tumor-induced wasting, " Journal of Cell Science, vol. 122, part 8, pp. 1119-1125, 2009.
24. M. Opreanu, M. Tikhonenko, S. Bozack, et al., "The unconventional role of acid sphingomyelinase in regulation of retinal microangiopathy in diabetic human and animal models, " Diabetes, vol. 60, no. 9, pp. 2370-2378, 2011.
25. G. Schiavoni, L. Gabriele, and F. Mattei, "The tumor microenvironment: a pitch for multiple players, " Frontiers in Oncology, vol. 3, article 90, 2013.
26. P. C. Rodriguez, D. G. Quiceno, and A. C. Ochoa, "Larginine availability regulates T-lymphocyte cell-cycle progression, " Blood, vol. 109, no. 4, pp. 1568-1573, 2007.
27. S. Ostrand-Rosenberg, P. Sinha, D. W. Beury, and V. K. Clements, "Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression, " Seminars in Cancer Biology, vol. 22, no. 4, pp. 275-281, 2012.
28. E. Gulbins and R. Kolesnick, "Raft ceramide in molecular medicine, " Oncogene, vol. 22, no. 45, pp. 7070-7077, 2003.
29. S. Lacour, A. Hammann, S. Grazide, et al., "Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells, " Cancer Research, vol. 64, no. 10, pp. 3593-3598, 2004.
30. S. Brunelli, C. Sciorati, G. DAntona, et al., "Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy, " Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 1, pp. 264-269, 2007.
31. Y. H. Zeidan and Y. A. Hannun, "Activation of acid sphingomyelinase by protein kinase Cdelta-mediated phosphorylation, " The Journal of Biological Chemistry, vol. 282, no. 15, pp. 11549-11561, 2007.
32. M. Garcia-Barros, D. Lacorazza, H. Petrie, et al., "Host acid sphingomyelinase regulates microvascular function not tumor immunity, " Cancer Research, vol. 64, no. 22, pp. 8285-8291, 2004.
33. E. L. Smith and E. H. Schuchman, "Acid sphingomyelinase overexpression enhances the antineoplastic effects of irradiation in vitro and in vivo, " Molecular Therapy, vol. 16, no. 9, pp. 1565-1571, 2008.
34. J. Kanterman, M. Sade-Feldman, and M. Baniyash, "New insights into chronic inflammation-induced immunosuppression, " Seminars in Cancer Biology, vol. 22, no. 4, pp. 307-318, 2012.
35. S.-K. Leivonen and V.-M. Kahari, "Transforming growth factor-β signaling in cancer invasion and metastasis, " International Journal of Cancer, vol. 121, no. 10, pp. 2119-2124, 2007.
36. J. Kim, R. L. Modlin, R. L. Moy, et al., "IL-10 production in cutaneous basal and squamous cell carcinomas: a mechanism for evading the local T cell immune response, " Journal of Immunology, vol. 155, no. 4, pp. 2240-2247, 1995.
37. S. Mocellin, F. M. Marincola, and H. A. Young, "Interleukin and the immune response against cancer: a counterpoint, " Journal of Leukocyte Biology, vol. 78, no. 5, pp. 1043-1051, 2005.
38. S. Tikoo and N. K. Haass, "Friends or foes: IL-10 and TGFbeta in melanoma, " Experimental Dermatology, vol. 24, no. 4, pp. 254-255, 2015.
39. V. Umansky and A. Sevko, "Melanoma-induced immunosuppression and its neutralization, " Seminars in Cancer Biology, vol. 22, no. 4, pp. 319-326, 2012.
40. E. Schlecker, A. Stojanovic, C. Eisen, et al., "Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth, " Journal of Immunology, vol. 189, no. 12, pp. 5602-5611, 2012.
41. P. Stoitzner, L. K. Green, J. Y. Jung, et al., "Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells, " Cancer Immunology, Immunotherapy, vol. 57, no. 11, pp. 1665-1673, 2008.
42. H. Ataera, E. Hyde, K. M. Price, P. Stoitzner, and F. Ronchese, "Murine melanoma-infiltrating dendritic cells are defective in antigen presenting function regardless of the presence of CD4+CD25+ regulatory T cells, " PLoSONE, vol. 6, no. 3, Article ID e17515, 2011.
43. W. Zou, "Regulatory T cells, tumour immunity and immunotherapy, " Nature Reviews Immunology, vol. 6, no. 4, pp. 295-307, 2006.
44. M. J. Dobrzanski, J. B. Reome, and R. W. Dutton, "Type 1 and type 2 CD8+ effector T cell subpopulations promote longterm tumor immunity and protection to progressively growing tumor, " Journal of Immunology, vol. 164, no. 2, pp. 916-925, 2000.
45. B. J. G. Baaten, C.-R. Li, and L. M. Bradley, "Multifaceted regulation of T cells by CD44, " Communicative and Integrative Biology, vol. 3, no. 6, pp. 508-512, 2010.
46. R. W. Dutton, L. M. Bradley, and S. L. Swain, "T cell memory, " Annual Review of Immunology, vol. 16, pp. 201-223, 1998.
47. Y. Ma, G. V. Shurin, Z. Peiyuan, and M. R. Shurin, "Dendritic cells in the cancer microenvironment, " Journal of Cancer, vol. 4, no. 1, pp. 36-44, 2013.
48. O. Preynat-Seauve, P. Schuler, E. Contassot, F. Beermann, B. Huard, and L. E. French, "Tumor-infiltrating dendritic cells are potent antigen-presenting cells able to activate T cells and mediate tumor rejection, " Journal of Immunology, vol. 176, no. 1, pp. 61-67, 2006.
49. F. Benencia, L. Sprague, J. McGinty, M. Pate, and M. Muccioli, "Dendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccination, " Journal of Biomedicine and Biotechnology, vol. 2012, Article ID 425476, 15 pages, 2012.
50. C. P. Duong, C. S. Yong, M. H. Kershaw, C. Y. Slaney, and P. K. Darcy, "Cancer immunotherapy utilizing gene-modified T cells: from the bench to the clinic, " Molecular Immunology, 2015.
51. O. Itzhaki, D. Levy, D. Zikich, et al., "Adoptive T-cell transfer in melanoma, " Immunotherapy, vol. 5, no. 1, pp. 79-90, 2013.
52. G. Q. Phan and S. A. Rosenberg, "Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy, " Cancer Control, vol. 20, no. 4, pp. 289-297, 2013.
53. J. M. Murray, A. M. Thompson, A. Vitsky, et al., "Nonclinical safety assessment of recombinant human acid sphingomyelinase (rhASM) for the treatment of acid sphingomyelinase deficiency: the utility of animal models of disease in the toxicological evaluation of potential therapeutics, " Molecular Genetics and Metabolism, vol. 114, no. 2, pp. 217-225, 2015.
54. C. Perrotta and E. Clementi, "Biological roles of acid and neutral sphingomyelinases and their regulation by nitric oxide, " Physiology, vol. 25, no. 2, pp. 64-71, 2010.
55. D. Cervia, C. Perrotta, C. Moscheni, C. de Palma, and E. Clementi, "Nitric oxide and sphingolipids control apoptosis and autophagy with a significant impact on Alzheimers disease, " Journal of Biological Regulators and Homeostatic Agents, vol. 27, no. 2, supplement, pp. 11-22, 2013.
56. E. Assi, D. Cazzato, C. De Palma, C. Perrotta, E. Clementi, and D. Cervia, "Sphingolipids and brain resident macrophages in neuroinflammation: an emerging aspect of nervous system pathology, " Clinical and Developmental Immunology, vol. 2013, Article ID 309302, 8 pages, 2013.
57. C. Perrotta, L. Bizzozero, D. Cazzato, et al., "Syntaxin 4 is required for acid sphingomyelinase activity and apoptotic function, " Journal of Biological Chemistry, vol. 285, no. 51, pp. 40240-40251, 2010.
58. Y. Li, S. Li, X. Qin, et al., "The pleiotropic roles of sphingolipid signaling in autophagy, " Cell Death and Disease, vol. 5, no. 5, Article ID e1245, 2014.
59. F. C. Luft, "Acid sphingomyelinase, autophagy, and atherosclerosis, " Journal ofMolecularMedicine, vol. 92, no. 5, pp. 429-431, 2014.
60. C. Garcia-Ruiz, J. M. Mato, D. Vance, N. Kaplowitz, and J. C. Fernand ez-Checa, "Acid sphingomyelinase-ceramide system in steatohepatitis: a novel target regulating multiple pathways, " Journal of Hepatology, vol. 62, no. 1, pp. 219-233, 2015.
61. C. Perrotta, D. Cervia, C. de Palma, et al., "The emerging role of Acid Sphingomyelinase in autophagy, " Apoptosis, vol. 20, no. 5, pp. 635-644, 2015.